Lendlease builds large-scale vaccine facility

The project aims to boost Singapore's biopharmaceutical sector.

Lendlease announced the construction of a large greenfield vaccine facility on 7 October.

The new facility's goal is to leverage Lendlease's digital capabilities and best practices in construction and underscore the company's accelerated growth in the life science sector as a sector of focus.

Managing director Ng Hsueh Ling said, "These project wins are a testament to Lendlease's ability to deliver facilities with the highest standards of safety, quality and efficiency. We are humbled to be working alongside many of the world's biggest pharmaceutical and biotechnology companies to help realise Singapore's ambition to be the next-generation hub for life sciences."

"The life sciences sector is one of our key focus areas, where we are looking to apply our expertise across the integrated real estate value chain. As we continue to expand our experience and elevate Lendlease's life science integrated development capabilities, I am confident that Lendlease is well-poised in providing one of the best end-to-end solutions for future projects across Asia," added Asia CEO Justin Gabbani.

Lendlease has built the majority of Singapore's major pharmaceutical facilities and more than 90% of the biotechnology facilities in the island state's Tuas Biomedical Park, a 280-hectare specialised industrial park that is master-planned and developed by JTC since the late 1990s.